# US 2016/0355586 A1 · Covalent Diabodies and Uses Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0355586 A1
- Document ID: US20160355586A1
- Status: Published application
- Kind: A1
- Application number: 15/040,774
- Filed: 2016-02-10
- Published: 2016-12-08
- Earliest claimed: 2005-04-15
- Assignees: MacroGenics, Inc.
- Applicants: MacroGenics, Inc.
- Inventors: Leslie S. Johnson; Ling Huang
- Web page: https://patentgrep.com/patent/US20160355586A1

## CPC

- C07K 16/283: {against Fc-receptors, e.g. CD16, CD32, CD64 (CD23 C07K16/2851)}
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/626: Diabody or triabody
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention is directed to diabody molecules and uses thereof in the treatment of a variety of diseases and disorders, including immunological disorders, infectious disease, intoxication and cancers. The diabody molecules of the invention comprise two polypeptide chains that associate to form at least two epitope binding sites, which may recognize the same or different epitopes on the same or differing antigens. Additionally, the antigens may be from the same or different molecules. The individual polypeptide chains of the diabody molecule may be covalently bound through non-peptide bond covalent bonds, such as, but not limited to, disulfide bonding of cysteine residues located within each polypeptide chain. In particular embodiments, the diabody molecules of the present invention further comprise an Fc region, which allows antibody-like functionality to engineered into the molecule.

## Claims

### Claim 1

A diabody molecule comprising a first polypeptide chain and a second polypeptide chain, said chains each having an N-terminus and a C-terminus and being covalently bonded to one another, wherein:
(A) said first polypeptide chain comprises, in the N-terminal to C-terminal direction:
(i) a first domain comprising an epitope-binding region of a light chain variable domain of a first immunoglobulin (VL1) specific for a first epitope,
(ii) a second domain comprising an epitope-binding region of a heavy chain variable domain of a second immunoglobulin (VH2) specific for a second epitope, and
(iii) a third domain comprising an Fc domain or portion thereof,
wherein said VL1 and said VH2 are covalently linked by a peptide linker such that said VL1 and said VH2 do not associate with one another to form an epitope binding site capable of specifically binding said first or second epitope; and
(B) which second polypeptide chain comprises, in the N-terminal to C-terminal direction:
(i) a fourth domain comprising an epitope-binding region of a light chain variable domain of the second immunoglobulin (VL2),
(ii) a fifth domain comprising an epitope-binding region of a heavy chain variable domain of the first immunoglobulin (VH1), and
(iii) a sixth domain comprising an Fc domain,
wherein said VL2 and said VH1 are covalently linked by a peptide linker such that said VL2 and said VH1 do not associate with one another to form an epitope binding site capable of specifically binding said first or second epitope;
wherein the first domain and the fifth domain associate to form a first (VL1)(VH1) binding site capable of specifically binding the first epitope;
wherein the second domain and the fourth domain associate to form a (VL2)(VH2) binding site capable of specifically binding the second epitope; and
wherein:
(1) said second and said third domains; and/or
(2) said fifth and said sixth domains;
are linked to one another by an intervening polypeptide linker having a sequence selected from the group consisting of SEQ ID NOs.:278, 280, 281, 283, 284, 286, 287, 288, 289, 290, 293, 295 and 297.

### Claim 2 (depends on 1)

The diabody molecule of claim 1, wherein the third domain comprises a hinge-Fc domain, said hinge portion thereof being a cysteine-containing hinge domain that comprises the amino acid sequence: VEPKSC (SEQ ID NO:77) or a valine to alanine substitution thereof.

### Claim 3

A diabody molecule comprising a first polypeptide chain and a second polypeptide chain, said chains each having an N-terminus and a C-terminus and being covalently bonded to one another, wherein:
(A) said first polypeptide chain comprises, in the N-terminal to C-terminal direction:
(i) a first domain comprising an epitope-binding region of a light chain variable domain of a first immunoglobulin (VL1) specific for a first epitope,
(ii) a second domain comprising an epitope-binding region of a heavy chain variable domain of a second immunoglobulin (VH2) specific for a second epitope, and
(iii) a third domain comprising a cysteine residue and an Fc domain or portion thereof,
wherein said VL1 and said VH2 are covalently linked by a peptide linker such that said VL1 and said VH2 do not associate with one another to form an epitope binding site capable of specifically binding said first or second epitope; and
(B) which second polypeptide chain comprises, in the N-terminal to C-terminal direction:
(i) a fourth domain comprising an epitope-binding region of a light chain variable domain of the second immunoglobulin (VL2),
(ii) a fifth domain comprising an epitope-binding region of a heavy chain variable domain of the first immunoglobulin (VH1), and
(iii) a sixth domain comprising a cysteine residue,
wherein said VL2 and said VH1 are covalently linked by a peptide linker such that said VL2 and said VH1 do not associate with one another to form an epitope binding site capable of specifically binding said first or second epitope;
wherein the first domain and the fifth domain associate to form a (VL1)(VH1) binding site capable of specifically binding the first epitope;
wherein the second domain and the fourth domain associate to form a (VL2)(VH2) binding site capable of specifically binding the second epitope; and
wherein:
(1) said second and said third domains; or
(2) said fifth and said sixth domains;
are linked to one another by an intervening polypeptide linker having a sequence selected from the group consisting of SEQ ID NOs.: 278, 280, 281, 283, 284, 286, 287, 288, 289, 290, 293, 295 and 297.

### Claim 4

A diabody molecule comprising a first polypeptide chain and a second polypeptide chain, said chains each having an N-terminus and a C-terminus and being covalently bonded to one another, wherein:
(A) said first polypeptide chain comprises, in the N-terminal to C-terminal direction:
(i) a first domain comprising an epitope-binding region of a light chain variable domain of a first immunoglobulin (VL1) specific for a first epitope,
(ii) a second domain comprising an epitope-binding region of a heavy chain variable domain of a second immunoglobulin (VH2) specific for a second epitope, and
(iii) a third domain comprising a cysteine residue,
wherein said VL1 and said VH2 are covalently linked by a peptide linker such that said VL1 and said VH2 do not associate with one another to form an epitope binding site capable of specifically binding said first or second epitope; and
(B) which second polypeptide chain comprises, in the N-terminal to C-terminal direction:
(i) a fourth domain comprising an epitope-binding region of a light chain variable domain of the second immunoglobulin (VL2),
(ii) a fifth domain comprising an epitope-binding region of a heavy chain variable domain of the first immunoglobulin (VH1), and
(iii) a sixth domain comprising a cysteine residue,
wherein said VL2 and said VH1 are covalently linked by a peptide linker such that said VL2 and said VH1 do not associate with one another to form an epitope binding site capable of specifically binding said first or second epitope;
wherein the first domain and the fifth domain associate to form a (VL1)(VH1) binding site capable of specifically binding the first epitope;
wherein the second domain and the fourth domain associate to form a (VL2)(VH2) binding site capable of specifically binding the second epitope; and
wherein:
(1) said second and said third domains; and/or
(2) said fifth and said sixth domains;
are linked to one another by an intervening polypeptide linker having a sequence selected from the group consisting of SEQ ID NOs.: 278, 280, 281, 283, 284, 286, 287, 288, 289, 290, 293, 295 and 297.

### Claim 5

A diabody molecule comprising a first polypeptide chain and a second polypeptide chain, said chains each having an N-terminus and a C-terminus and being covalently bonded to one another, wherein:
(A) said first polypeptide chain comprises, in the N-terminal to C-terminal direction:
(i) a third domain comprising an Fc domain or portion thereof,
(ii) a first domain comprising an epitope-binding region of a light chain variable domain of a first immunoglobulin (VL1) specific for a first epitope, and
(iii) a second domain comprising an epitope-binding region of a heavy chain variable domain of a second immunoglobulin (VH2) specific for a second epitope,
wherein said VL1 and said VH2 are covalently linked by a peptide linker such that said VL1 and said V112 do not associate with one another to form an epitope binding site capable of specifically binding said first or second epitope; and
(B) which second polypeptide chain comprises, in the N-terminal to C-terminal direction:
(i) a fourth domain comprising an epitope-binding region of a light chain variable domain of the second immunoglobulin (VL2),
(ii) a fifth domain comprising an epitope-binding region of a heavy chain variable domain of the first immunoglobulin (VH1),
wherein said VL2 and said VH1 are covalently linked by a peptide linker such that said VL2 and said VH1 do not associate with one another to form an epitope binding site capable of specifically binding said first or second epitope;
wherein the first domain and the fifth domain associate to form a (VL1)(VH1) binding site capable of specifically binding the first epitope;
wherein the second domain and the fourth domain associate to form a (VL2)(VH2) binding site capable of specifically binding the second epitope; and
wherein said third and first domains are linked to one another by an intervening polypeptide linker having a sequence selected from the group consisting of SEQ ID NOs.: 278, 280, 281, 283, 284, 286, 287, 288, 289, 290, 293, 295 and 297.

### Claim 6 (depends on 5)

The diabody molecule of claim 5, wherein the third domain comprises a hinge-Fc domain, said hinge portion thereof being a cysteine-containing hinge domain that comprises the amino acid sequence: VEPKSC (SEQ ID NO:77) or a valine to alanine substitution thereof.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The diabody molecule of any one of claims 1-6, wherein one of said (VL1)(VH1) and (VL2)(VH2) binding sites is capable of specifically binding to an epitope of CD32B, and the other of said (VL1)(VH1) and (VL2)(VH2) binding sites is capable of specifically binding to an epitope of CD16.

### Claim 8

A diabody molecule comprising a first polypeptide chain and a second polypeptide chain, said chains each having an N-terminus and a C-terminus and being covalently bonded to one another, wherein:
(A) said first polypeptide chain comprises, in the N-terminal to C-terminal direction:
(i) a domain (A) comprising a binding region of a light chain variable domain of a first immunoglobulin (VL1) capable of specifically binding an epitope (1);
(ii) a domain (B) comprising a binding region of a heavy chain variable domain of a second immunoglobulin (VH2) capable of specifically binding an epitope (2); and
(iii) a cysteine-containing domain (C) comprising a light chain constant region (CL) domain or portion thereof;
(B) said second polypeptide chain comprises:
(i) a domain (D) comprising a binding region of a light chain variable domain of the second immunoglobulin (VL2) capable of specifically binding said epitope (2);
(ii) a domain (E) comprising a binding region of a heavy chain variable domain of the first immunoglobulin (VH1) capable of specifically binding said epitope (1);
(iii) a cysteine-containing domain (F) comprising a heavy chain constant region 1 (CH1) domain or portion thereof, a hinge region, a heavy chain constant region 2 (CH2) domain and a heavy chain constant region 3 (CH3) domain;
wherein:
said domains (A) and (B) do not associate with one another to form an epitope binding site capable of specifically binding said epitopes (1) or (2);
said domains (D) and (E) do not associate with one another to form an epitope binding site capable of specifically binding said epitopes (1) or (2);
said domains (A) and (E) associate to form a binding site capable of specifically binding said epitope (1);
said domains (B) and (D) associate to form a binding site capable of specifically binding said epitope (2);
said domains (C) and (F) are associated together via a disulfide bond;
wherein:
(1) said domains (B) and (C); and/or
(2) said domains (E) and (F);
are linked to one another by an intervening polypeptide linker having a sequence selected from the group consisting of SEQ ID NOs.:278, 280, 281, 283, 284, 286, 287, 288, 289, 290, 293, 295 and 297.

### Claim 9 (depends on 8)

The diabody molecule of claim 8, wherein said molecule additionally comprises a third polypeptide chain and a fourth polypeptide chain, said third and fourth polypeptide chains each having an N-terminus and a C-terminus and being covalently bonded to one another wherein:
(A) said third polypeptide chain comprises, in the N-terminal to C-terminal direction:
(i) a domain (G) comprising a binding region of a light chain variable domain of a first immunoglobulin (VL1) capable of specifically binding an epitope (3);
(ii) a domain (H) comprising a binding region of a heavy chain variable domain of a second immunoglobulin (VH2) capable of specifically binding an epitope (4); and
(iii) a cysteine-comprising domain (I) comprising a light chain constant region (CL) domain or portion thereof;
(B) said fourth polypeptide chain comprises:
(i) a domain (J) comprising a binding region of a light chain variable domain of the second immunoglobulin (VL2) capable of specifically binding said epitope (4);
(ii) a domain (K) comprising a binding region of a heavy chain variable domain of the first immunoglobulin (VH1) capable of specifically binding said epitope (3);
(iii) a cysteine-comprising domain (L) comprising a heavy chain constant region 1 (CH1) domain or portion thereof, a hinge region, a heavy chain constant region 2 (CH2) domain and a heavy chain constant region 3 (CH3) domain;
wherein:
said domains (G) and (H) do not associate with one another to form an epitope binding site capable of specifically binding said epitopes (3) or (4);
said domains (J) and (K) do not associate with one another to form an epitope binding site capable of specifically binding said epitopes (3) or (4);
said domains (G) and (K) associate to form a binding site capable of specifically binding said epitope (3);
said domains (H) and (J) associate to form a binding site capable of specifically binding said epitope (4);
said domains (I) and (L) are associated together via a disulfide bond; and
said hinge region, heavy chain constant region 2 (CH2) and said heavy chain constant region 3 (CH3) of said second and fourth polypeptide chains associate to form an Fc region; and
wherein:
(1) said domains (H) and (I); and/or
(2) said domains (K) and (L);
are optionally linked to one another by an intervening polypeptide linker having a sequence selected from the group consisting of SEQ ID NOs.: 278, 280, 281, 283, 284, 286, 287, 288, 289, 290, 293, 295 and 297.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6)

The diabody molecule of any one of claims 1-6, wherein at least one of said first or said second polypeptide chains of said diabody molecule additionally comprise an E-coil or a K-coil separator.

### Claim 11 (depends on 10)

The diabody molecule of claim 10, wherein said first polypeptide chain comprises an E-coil separator and said second polypeptide chain comprises a K-coil separator or said first polypeptide chain comprises a K-coil separator and said second polypeptide chains comprises an E-coil separator.

### Claim at position 12

12-13. (canceled)

### Claim 14 (depends on 10)

The diabody molecule of claim 10, wherein said at least one of E-coil or a K-coil separator is linked to a polypeptide portion of an albumin-binding domain 3 (ABD3) of protein G of Streptococcus strain G148.

### Claim at position 14

15-16. (canceled)

### Claim 17 (depends on 11)

The diabody molecule of claim 11, wherein said E-coil or K-coil separator is linked to a polypeptide portion of an albumin-binding domain 3 (ABD3) of protein G of Streptococcus strain G148.

### Claim at position 16

18-30. (canceled)

### Claim 31 (depends on 1)

The diabody molecule of claim 1, wherein one of said first or second polypeptide chains comprises a knob mutation in said chain's Fc domain.

### Claim 32 (depends on 31)

The diabody molecule of claim 31, wherein one of said first or second polypeptide chains comprises said knob mutation in said chain's Fc domain, and the other of said first or second polypeptide chains comprises a hole mutation in said chain's Fc domain.

### Claim 33 (depends on 9)

The diabody molecule of claim 9, wherein one of said second or fourth polypeptide chains comprises a knob mutation in said CH2 or CH3 domain of said chain.

### Claim 34 (depends on 33)

The diabody molecule of claim 33, wherein one of said second or fourth polypeptide chains comprises said knob mutation in said chain's Fc domain, and the other of said second or fourth polypeptide chains comprises a hole mutation in said chain's Fc domain.
